Bristol won’t seek faster Opdivo/Yervoy lung cancer approval | International News Live Blog

https://internationalnewsliveblog.wordpress.com/2017/01/20/bristol-wont-seek-faster-opdivoyervoy-lung-cancer-approval/

(Reuters) – Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer. http://internationalnewslive.com/bristol-wont-seek-faster-opdivoyervoy-lung-cancer-approval/